CRSP

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

CRISPR Therapeutics presents new preclinical data for CTX460™ demonstrating in vivo gene correction of alpha-1 antitrypsin deficiency using novel SyNTase™ editing platformOct 10, 2025
CRISPR Therapeutics to present preclinical data on alpha-1 antitrypsin deficiency (AATD) utilizing novel SyNTase gene editing technology at ESGCT 2025 annual congressOct 1, 2025
CRISPR Therapeutics and Sirius Therapeutics announce first patient dosed in Phase 2 trial of SRSD107 for thromboembolic disorders in EuropeSep 22, 2025
CRISPR Therapeutics reports positive additional Phase 1 data for CTX310™ targeting ANGPTL3 and provides update on cardiovascular pipelineJun 26, 2025